[ad_1]
The cure of the century could be near, as a team of researchers announced this weekend the possible vaccine against HIV, which provoked an immune response in humans and rhesus monkeys.
The study published Saturday in the journal "The Lancet" shows the result of a test conducted on 393 adults, who did not have the virus, between 18 and 50 years, in several countries African countries, Thailand and the United States.
The application of the vaccine has caused them an immune system response against several strains of HIV
We recommend:
Study participants received four doses of the vaccine for 48 weeks. There were seven types of drug combinations plus a placebo that were administered to all participants.
Novel #HIV candidate vaccine is safe and induces an immune response in healthy adults and monkeys-results of an evaluation of an HIV-1 mosaic vaccine in a Phase 1 / 2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) https://t.co/vrYCEZMlSc pic.twitter.com/cYEICM2uo1
– The Lancet (@TheLancet) July 6, 2018
The vaccine was also safe, although some participants in the trial experienced mild disorders such as abdominal pain, diarrhea, dizziness, and back pain
]. The results represent an important step, but getting an immune response to HIV does not mean that it completely protects humans from the virus, "said Dan Barouch, director of the Virology and Vaccine Research Center at Beth Israel. Deaconess Medical Center.
In the article published in the networks by The Lancet, it is assured that in 2016 more than 18 million new cases of HIV-1 infection were diagnosed in the world and that there is no prophylactic vaccine allowed to fight it.
"Our goal was to evaluate candidates for HIV-1 vaccine-based mosaic adenovirus serotype 26 (Ad26) in parallel studies in humans and rhesus monkeys to define the optimal vaccine regimen to advance clinical efficacy trials. "
[ad_2]
Source link
